Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 5 - Drugs for disorders of the endocrine system
Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
08/2003
08/07/2003CA2474649A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
08/07/2003CA2473810A1 Fgfr agonists
08/07/2003CA2473249A1 New corticosteroids
08/07/2003CA2473162A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
08/07/2003CA2443023A1 8-heteroaryl xanthine adenosine a2b receptor antagonists
08/06/2003EP1332762A1 Method of treating hyperprolactinemia and prolactinomas
08/06/2003EP1332372A2 Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression
08/06/2003EP1332133A1 Metabotropic glutamate receptor antagonists
08/06/2003EP1331972A2 Pharmaceutical compositions
08/06/2003EP1331943A2 Nucleic acid molecules and polypeptides for immune modulation
08/06/2003EP1331935A2 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
08/06/2003EP1212345B1 Orally active 7-alpha-alkyl androgens
08/06/2003EP1117648B1 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors
08/06/2003EP0914148B1 Treatment of partial growth hormone insensitivity syndrome
08/06/2003CN1434865A Regulation effect of conjugated frame transport protein ABC1
08/06/2003CN1434823A 3-thiazol-4-yl-pyprolidine derivatives as AMP-specific phosphodiesterase inhibitors
08/06/2003CN1434820A Cyclic AMP-specific phosphodiesterase inhibitors
08/06/2003CN1434817A Pyrazole cyclic AMP-specific PDE inhibitors
08/06/2003CN1434799A Cyclic amp-specific phosphodiesterase inhibitors
08/06/2003CN1434797A Hydrazone and oxime derivatives of pyrrolidine as AMP-specific phosphodiesterase inhibitons
08/06/2003CN1434707A Method and compositions for preventing hormone induced adverse effects
08/06/2003CN1117092C Azadicyclic compound, its medicinal composition and medicinal use
08/06/2003CN1116872C Medicament product
08/05/2003US6603002 Process and intermediates for growth hormone secretagogues
08/05/2003US6602901 Antidiabetic agents, obesity
08/05/2003US6602856 Antagonists of alpha-melanocyte stimulating hormone and methods based thereon
07/2003
07/31/2003WO2003062276A2 Multimers of receptor-binding ligands
07/31/2003WO2003062275A1 Glycoisoforms of adiponectin and uses thereof
07/31/2003WO2003062259A2 Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
07/31/2003WO2003062252A1 Edg receptor agonists
07/31/2003WO2003062241A1 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function
07/31/2003WO2003061664A1 Orodispersible pharmaceutical composition comprising testosterone
07/31/2003WO2003061651A1 Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
07/31/2003WO2003061648A1 Use of cholinesterase antagonists to treat insulin resistance
07/31/2003WO2003061634A1 Sustained release pharmaceutical composition
07/31/2003WO2003061573A2 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
07/31/2003WO2003061557A2 Levothyroxine pharmaceutical compositions, methods of making and methods of administration
07/31/2003WO2003061362A2 Methods and compositions for treating polycystic ovary syndrome
07/31/2003WO2003041649A3 Cyanoalkylamino derivatives as protease inhibitors
07/31/2003WO2003035668A3 Novel anti-inflammatory androstane derivatives -17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha
07/31/2003WO2003018545B1 24-sulfur-substituted analogs of 1α,25-dihydroxy vitamin d¿3?
07/31/2003WO2002030514A3 Insulin receptor activators for the treatment of metabolic disorders in humans resulting from treatment of hiv infection with hiv protease inhibitors
07/31/2003US20030144526 Calcium receptor-active compounds
07/31/2003US20030144516 Crystalline form VII of cabergoline
07/31/2003US20030144359 Dermatological use and a dermatological preparation
07/31/2003US20030144347 Method for treating autoimmune disease
07/31/2003US20030144337 Pyrazole-derived kinase inhibitors and uses thereof
07/31/2003US20030144313 Non-steroidal, tetracylic compounds for estrogen-related treatments
07/31/2003US20030144298 Therapeutic combinations of antihypertensive and antiangiogenics agents
07/31/2003US20030144279 5-Heterocyclo-pyrazoles
07/31/2003US20030144267 Novel compounds
07/31/2003US20030144203 Methods for slowing senescence and treating and preventing diseases associated with senescence
07/31/2003US20030143690 Peptides and proteins that effect protein phosphorylation; genetic engineered DNA; useful for therapy and diagnosis
07/31/2003US20030143676 Receptor polypeptides and polynucleotides encoding such polypeptides; for treating a disorder characterized by an elevated level of osteopontin
07/31/2003US20030143589 Drug metabolizing enzymes
07/31/2003US20030143271 For therapy and prophylaxis of cyclooxygenase-2 mediated disorder and for providing cardioprotection
07/31/2003CA2514088A1 Use of cholinesterase antagonists to treat insulin resistance
07/31/2003CA2510751A1 Multimers of receptor-binding ligands
07/31/2003CA2474292A1 Sustained release pharmaceutical composition
07/31/2003CA2473927A1 Methods and compositions for treating polycystic ovary syndrome
07/31/2003CA2473781A1 Glycoisoforms of adiponectin and uses thereof
07/31/2003CA2471342A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
07/30/2003EP1330468A1 Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids
07/30/2003EP1330455A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
07/30/2003EP1330451A2 Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators
07/30/2003EP1330293A2 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same
07/30/2003EP1330156A1 Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of socs sequence in the animal
07/30/2003EP1184388B1 Sulphostin analogues and processes for the preparation of sulphostin and analogues thereof
07/30/2003EP1171100B1 Solubilized pharmaceutical composition for parenteral administration
07/30/2003EP1135403B1 17beta-acyl-17alpha-propynyl-11beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties
07/30/2003EP1112275B1 Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
07/30/2003EP0942780B1 Coated particles, methods of making and using
07/30/2003EP0941067B1 Stable glassy state powder formulations
07/30/2003EP0902022B1 Novel benzofuranone derivatives and process for producing the same
07/30/2003CN1433426A 16,17-carbocyclic condensed steroid compounds having seletive estrogenic activeity
07/30/2003CN1433425A Unsaturated 14,15-cyclopropane-cendrostanes, a method for their production and pharmaceutical compositions containing these compounds
07/30/2003CN1433424A 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens
07/30/2003CN1433411A Chemical compounds
07/30/2003CN1433401A New phenalkyloxy-phenyl derivatives
07/30/2003CN1433311A Methods for making sustained release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
07/30/2003CN1116042C Coposition containing chlopidogrel and antithrombotic agent active component
07/29/2003WO2004065614A2 Suppression of cytotoxic protein conformers
07/29/2003US6600039 Using potassium-t-butylate in tetrahydrofuran. it is not easy to carry out the process under industrial conditions, yield is low, the product is contaminated, its purification requires repeated crystallization. that by stirring in dimethyl
07/29/2003US6600015 Treatment or prevention of obesity.
07/29/2003US6599925 Cardiovascular disorders; anticancer agents
07/29/2003US6599923 Insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action
07/29/2003US6599876 Medicament and method for treating renal disease
07/29/2003US6599627 Microencapsulation of drugs by solvent exchange
07/29/2003CA2473102A1 Suppression of cytotoxic protein conformers
07/29/2003CA2244621C 4-aminopyrrole (3,2-d) pyrimidines as neuropeptide y receptor antagonists
07/29/2003CA2180119C The composition containing snapping turtle and tortoise, the preparation and the use thereof
07/29/2003CA2123514C Novel benzothiophene derivative
07/24/2003WO2003060130A2 Pim-3 kinase as a target for type 2 diabetes mellitus
07/24/2003WO2003060096A2 Assay for the detection of factors that modulate the expression of ingap
07/24/2003WO2003059899A1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
07/24/2003WO2003059893A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases
07/24/2003WO2003059357A1 Pregnane steroids for use in the treatment of cns disorders
07/24/2003WO2003059329A2 Polytartrate composition
07/24/2003WO2003059293A2 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators
07/24/2003WO2003059283A2 Compounds for blocking androgen receptors
1 ... 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 ... 290